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Abstract: 
Background: Fullerenes are molecules being investigated for a wide range of therapeutic 
applications. We have shown previously that certain fullerene derivatives (FDs) inhibit mast cell 
(MC) function in vitro, and here we examine their in vivo therapeutic effect on asthma, a disease 
in which MCs play a predominant role. 
Objective: We sought to determine whether an efficient MC-stabilizing FD (C70-tetraglycolate 
[TGA]) can inhibit asthma pathogenesis in vivo and to examine its in vivo mechanism of action. 
Methods: Asthma was induced in mice, and animals were treated intranasally with TGA either 
simultaneously with treatment or after induction of pathogenesis. The efficacy of TGA was 
determined through the measurement of airway inflammation, bronchoconstriction, serum IgE 
levels, and bronchoalveolar lavage fluid cytokine and eicosanoid levels. 
Results: We found that TGA-treated mice have significantly reduced airway inflammation, 
eosinophilia, and bronchoconstriction. The TGA treatments are effective, even when given after 
disease is established. Moreover, we report a novel inhibitory mechanism because TGA 
stimulates the production of an anti-inflammatory P-450 eicosanoid metabolites (cis-
epoxyeicosatrienoic acids [EETs]) in the lung. Inhibitors of these anti-inflammatory EETs 
reversed TGA inhibition. In human lung MCs incubated with TGA, there was a significant 
upregulation of CYP1B gene expression, and TGA also reduced IgE production from B cells. 
Lastly, MCs incubated with EET and challenged through FcεRI had a significant blunting of 
mediator release compared with nontreated cells. 
Conclusion: The inhibitory capabilities of TGA reported here suggest that FDs might be used a 
platform for developing treatments for asthma. 
Abbreviations used: ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; BALF, 
Bronchoalveolar lavage fluid; EET, Cis-epoxyeicosatrienoic acid; FD, Fullerene derivative; MC, 
Mast cell; OVA, Ovalbumin; PPOH, 6-(2-Propargyloxyphenyl) hexanoic acid; TGA, C70-
tetraglycolate 
Fullerene derivative | eicosanoids | asthma | airway inflammation | Keywords: 
bronchoconstriction | allergy 
Article: 
In asthmatic patients the massive influx of immune cells, particularly eosinophils, causes airway 
thickening and reduced airflow into the lungs.1 Eicosanoids, including leukotrienes and 
prostaglandins, are rapidly produced by immune cells to initiate inflammation.2 Cytokines 
maintain chronic inflammation because IL-4 and IL-13 stimulate B-cell class-switching to IgE, 
IL-13 also promotes goblet cell metaplasia and mucus overproduction, and IL-5 recruits and 
stimulates eosinophils.3 The airways also become hyperreactive with smooth muscle contraction 
and mast cell (MC) activation. Breathing difficulty manifests as wheezing, which can become 
life-threatening in severe cases. Although the causative allergens are not always identified, in 
patients with allergic asthma, degranulated MCs are found in lung tissue, and patient serum 
contains increased antigen-specific IgE and tryptase levels.4 MCs are thought to play an 
important role in pathogenesis because significant numbers are recruited to the airways and 
because MC degranulation products are found in the bronchoalveolar lavage fluid (BALF).5 In 
the murine asthma models that most closely mimic human disease, MC-deficient mice have 
reduced airway inflammation and bronchoconstriction in response to allergen challenge.6 and 7 
Fullerene derivatives (FDs) are nanospheres of carbon that have a unique ability to catalytically 
scavenge large numbers of oxygen free radicals, making them potentially useful for treating 
disease.8, 9 and 10 These robust antioxidants can reduce cellular damage and inflammation, and 
their therapeutic value has been suggested for the treatment of neurodegenerative and 
inflammatory diseases.11 and 12 Previous research has found that polyhydroxylated FDs can enter 
human lung MCs and suppress degranulation and inflammatory cytokine production after IgE 
cross-linking.13 Further studies have demonstrated that the biological function of FDs depends on 
the structure of the chemical moieties added to the carbon cage.14 Given that MCs play a role in 
the pathogenesis of allergic asthma and that FDs can stabilize MCs when challenged with 
activating stimuli, we hypothesized that FDs could prevent or possibly reverse the mechanisms 
leading to asthma. 
To test this hypothesis, we used an ovalbumin (OVA) challenge model of asthma to assess 
the in vivofunctionality of a novel FD (C70-tetraglycolate [TGA]) previously demonstrated to be 
an efficient in vitro MC stabilizer. 14 We find that whether TGA is administered before or after 
pathogenesis, it can significantly dampen airway inflammation in mice. In addition to reductions 
in eosinophil recruitment, airway hyperresponsiveness, and overall airway inflammation, 
significant reductions in IL-4 and IL-5 and serum IgE levels were also observed. TGA also 
suppressed IgE production by activated B cells. Furthermore, we have discovered a novel 
mechanism of action for TGA through the upregulation of the anti-inflammatory eicosanoid 
11,12-cis-epoxyeicosatrienoic acid (EET) and discovered these molecules can inhibit human MC 
mediator release in response to FcεRI challenge. TGA treatment causes no acute toxicity to mice 
because liver and kidney function are unaltered. Thus our results suggest that rationally designed 
FDs might provide an effective therapeutic option for the treatment of asthma and that induction 
of anti-inflammatory EETs represent a new strategy for asthma regulation. 
Methods 
Mice and reagents 
Chicken egg OVA, decamethonium bromide, and acetyl-β-methylcholine chloride 
(methacholine) were purchased from Sigma-Aldrich (St Louis, Mo). Aluminum hydroxide 
(alum) was purchased from Pierce (Rockford, Ill). Fullerene TGA was synthesized and tested at 
Luna Innovations, Inc (Roanoke, Va), as described previously.14 The EET inhibitor 14,15-EE-
5(Z)-E (an EET-specific antagonist)15 and EETs were obtained from Cayman Chemicals 
(Ann Arbor, Mich), and 6-(2-propargyloxyphenyl) hexanoic acid (PPOH; a selective inhibitor of 
epoxygenation catalyzed by CYP450 isozymes)16 was obtained from Sigma-Aldrich. Female 8- 
to 12-week-old C57BL/6 and BALB/c mice were purchased from Jackson Laboratory (Bar 
Harbor, Me). 
Murine asthma induction and tissue collection 
Acute asthma was induced as described by Williams and Galli7 because MCs are known to be 
important for this model. Mice were administered 20 μg of TGA intranasally every 3 days 
throughout the experiment. In some experiments the EET inhibitors (14,15-EE-5[Z]-E and 
PPOH) were administered intranasally 15 minutes before TGA inhalation by using 0.128 mg/kg 
in 20 μL. PPOH was also administered 2 hours after TGA inhalation at the same dose. Mice were 
killed on day 47, and BALF was collected by flushing the lungs with 1 mL of PBS. Supernatants 
were saved for cytokine analysis. Pelleted cells were spun onto slides and stained with the Hema 
3 stain set (Fisher Diagnostics, Middletown, Va). Percentages were determined by counting at 
least 100 leukocytes per slide. Lung tissue was fixed with 10% buffered formalin phosphate 
(Fisher Diagnostics) and embedded in paraffin at the VCU pathology core. Sections (5 μm) were 
cut onto slides and stained with hematoxylin and eosin. A Nikon eclipse with a SPOT Flex 
Shifting Pixel Color Mosaic (Diagnostic Instrumental, Inc, Sterling Heights, Mich) camera was 
used to photograph lung sections. All mouse protocols were approved by the VCU Institutional 
Care and Use Committee. 
A modified asthma model similar to that described by Williams and Galli7 was used to assess 
bronchoconstriction. In this model mice were sensitized with 4 injections of 50 μg of OVA and 
then challenged on days 22, 25, and 28 with 200 μg of OVA. Mice were killed on day 29, and 
bronchoconstriction was assessed with the Flexivent system (Scireq, Montreal, Quebec, Canada). 
Mice were anesthetized, and a 19-gauge blunt-end cannula was inserted into the trachea; 
ventilation began immediately. Mice were paralyzed by means of intraperitoneal injection of 0.5 
mg of decamethonium bromide. Lung function was assessed once it was determined that 
breathing was completely through mechanical ventilation. Responsiveness to methacholine was 
determined by exposing mice to aerosolized PBS and then to increasing doses (10, 25, 50, and 
100 mg/mL) of methacholine. Maximum airway resistance in response to each methacholine 
dose was determined by averaging the 3 highest values. 
Established asthma induction 
Mice were sensitized intraperitoneally and challenged intranasally, as in Fig 1, B, to determine 
whether TGA could reverse established disease. Intranasal treatment with 20 μg of TGA began 
on day 47 and continued every 3 days after. Mice were challenged again with 200 μg of OVA 
administered intranasally on days 66, 69, 72, and 75. On day 76, mice were killed, and data on 
airway hyperresponsiveness, BALF, and lung tissues were collected and assessed as above. 
 
 
Fig 1. A novel FD, C70-tetraglycolate, inhibits airway inflammation and bronchoconstriction in a murine 
model of asthma. A,Fullerene TGA consists of 4 glycolic acids covalently bonded to the fullerene 
C70 core, creating a water-soluble molecule.B, Schematic of the OVA challenge acute asthma model. 
Allergic lung inflammation was induced by means of intraperitoneal(i.p.) sensitization with OVA 
followed by 3 intranasal (i.n.) OVA challenges. Tetraglycolate was administered intranasally every 3 days 
starting on day −1. C, After OVA intranasal challenge, BALF and lung tissues were collected. The total 
number of cells (left) was counted with trypan blue and the total number of eosinophils (right) in BALF 
cells was counted by using Hema 3. Nonsensitized (NS) controls are shown for reference (n = 6-10 
animals per group). *P < .05 or **P < .001, as determined by using the Student t test. D and E, TGA-
treated mice survived to a higher dose of methacholine (Fig 1, D) and were less responsive to aerosolized 
methacholine compared with PBS-treated animals (Fig 1, E). F and G, In separate experiments using this 
model, lung tissues were fixed, sectioned, and stained with hematoxylin and eosin (Fig 1, F) and periodic 
acid–Schiff (Fig 1, G). Representative photographs show cellular infiltration into the airways of OVA-
sensitized mice treated with PBS or TGA. Arrows indicate areas of inflammation (magnification × 10) 
and eosinophils (magnification × 100). 
Human lung MC preparation and mediator release 
Human lung MCs were purified as described previously.17 and 18 Tissue procurement and 
institutional review board approval were obtained from the Cooperative Human Tissue Network. 
Purified cells were incubated for 16 hours (a time point determined to be optimal for inhibition, 
data not shown) with or without 3 different EETs, washed, and incubated with optimal 
concentrations of anti-FcεRI stimuli (1 μg/mL). Mediator release (degranulation and cytokine 
production) was determined as previously described.19 
B-cell IgE production and measurement 
Naive B cells isolated from spleens of BALB/c mice20 were treated with or without TGA (1 
μg/mL) before challenge with IL-4 (20 ng/mL) and anti-CD40 antibodies (1 μg/mL) for 8 days, 
and IgE levels were measured by means of ELISA. 
Quantitative analysis of eicosanoids by means of HPLC electrospray tandem mass spectrometry 
Three hundred microliters of ethanol was added to 300 μL of centrifuged BALF together with 10 
ng of each deuterated standard. Ten microliters of this mixture was resolved in a 30 minute 
reversed-phase HPLC method. A Kinetex C18 column (100 × 2.1 mm, 2.6 μm) was used to 
separate the eicosanoids at a flow rate of 200 μL/min at 50°C. Before sample injection, the 
column was equilibrated with 100% Solvent A (acetonitrile/water/formic acid [40:60:0.02 
vol/vol/vol]). One hundred percent Solvent A was used for the first minute of elution. Solvent B 
(acetonitrile/isopropanol [50:50 vol/vol]) was increased following a linear gradient to 25% 
Solvent B by 3 minutes, 45% Solvent B between 3 and 11 minutes, 60% Solvent B between 11 
and 13 minutes, 75% Solvent B between 13 and 18 minutes, and 100% Solvent B between 18 
and 20 minutes. The gradient was maintained at 100% Solvent B from 20 to 25 minutes and was 
then decreased to 0% by 26 minutes and held at 0% until 30 minutes. The eluting eicosanoids 
were analyzed by using an inline hybrid linear ion trap triple quadrapole tandem mass 
spectrometer (ABI 4000 Q-Trap; Applied Biosystems, Foster City, Calif) equipped with an 
electrospray ionization source operating in negative ion multiple-reaction monitoring mode. 
Eicosanoids were monitored by using relevant precursor → product multiple reaction monitoring 
(MRM pairs). Additional mass spectrometric parameters used are as follows: curtain gas, 30 psi; 
charged aerosol detection, high; ion spray voltage, −3500 V; temperature, 500°C; gas 1, 40 psi; 
gas 2, 60 psi; declustering potential, collision energy, and cell-exit potential vary per transition. 
ELISA and multiplex cytokine assay 
Mucin-5AC (Muc5AC) protein was measured by using ELISA, as previously described.21 BALF 
was diluted, and 75 μL was incubated with bicarbonate-carbonate buffer (75 μL) at 40°C in a 96-
well plate (Nunc) for a total volume/well of 150 μL until dry. Plates were washed 3 times with 
PBS and blocked with 2% BSA (Sigma-Aldrich) for 1 hour at room temperature. Plates were 
again washed 3 times with PBS and then incubated with 50 μL of murine Muc5AC mAb (1:100) 
and diluted with PBS containing 0.05% Tween 20 for 1 hour. Plates were washed 3 times with 
PBS, and 100 μL of horseradish peroxidase–goat anti-mouse IgG conjugate (1:10,000) diluted in 
blocking solution was added for an hour and washed. Color reaction was developed with 
3,3′,5,5′-tetramethylbenzidine peroxidase solution, stopped with 0.18 mol/L H2SO4, and 
measured at 450 nm. Cytokine levels in BALF were measured by using a multiplex cytokine 
assay (Bio-Rad Laboratories, Hercules, Calif). Total murine IgE levels were measured as 
described previously.22 Levels of the liver enzymes aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) were measured as described previously.17 Serum creatinine 
levels were measured according to the manufacturer's instructions (Arbor Assays, Ann Arbor, 
Mich). 
Results 
FD TGA inhibits airway eosinophilia and bronchoconstriction 
A panel of FDs was developed with the objective of finding compounds capable of inhibiting 
MC responses.14 The C70-based FD with 4 glycolic acids attached (TGA; Fig 1, A) was one of 
the most efficient inhibitors of MC degranulation and cytokine production in vitro, revealing its 
potential as an inhibitor of MC-driven diseases. Because asthma pathogenesis is strongly 
influenced by MC activation and mediator release, we examined the therapeutic potential of 
TGA in a murine model of asthma. To determine whether TGA could inhibit disease onset, we 
used an intranasal OVA challenge protocol, as described in Fig 1, B. TGA administered 
intranasally throughout OVA sensitization and challenge resulted in a reduction in both total 
inflammatory cell numbers and eosinophil infiltration of the airways (Fig 1, C). Eosinophil 
percentages decreased from approximately 50% ± 7% to 13% ± 4% (± SD) with TGA treatment. 
Additionally, TGA-treated animals were more resistant to methacholine-induced death ( Fig 
1, D) because they were able to survive higher doses of methacholine than untreated mice. 
Furthermore, TGA-treated mice had significantly less methacholine-induced airway resistance 
compared with that seen in vehicle (PBS)–treated control mice ( Fig 1, E). In lung sections 
stained with hematoxylin and eosin, TGA-treated animals had only a few small areas of mild 
inflammation ( Fig 1, F, top panel). Within these areas, eosinophil infiltration is clearly reduced 
in TGA-treated animals ( Fig 1, F, bottom, arrows indicate eosinophils). In contrast, several 
large areas of inflammation are seen in PBS-treated mice ( Fig 1, F, top), and many eosinophils 
are found within this inflammation ( Fig 1, F, bottom, arrows indicate eosinophils). Periodic 
acid–Schiff staining is marginally reduced in TGA-treated animals ( Fig 1, G); however, no 
differences in Muc5 RNA or protein levels were seen (not shown). These data indicate that TGA 
is able to dampen multiple features of IgE-dependent asthma pathogenesis, leading us to further 
investigate its mechanism of action. 
TGA dampens established disease 
Because asthma therapeutics are administered only after symptoms are established, we have 
developed a model to examine the effect of TGA on established disease. In this model (Fig 2, A) 
mice are sensitized and challenged with OVA before the initiation of TGA treatment. After 
disease initiation, mice are treated with TGA every 3 days for 20 days total. Mice then 
underwent a secondary OVA challenge and were subsequently sacrificed; BALF and lung tissues 
were assessed as before. Even after disease is established, TGA administration significantly 
reduced eosinophil infiltration of BALF and lung tissue ( Fig 2,B). Furthermore, IL-4 and IL-5 
levels were significantly reduced in BALF, suggesting an overall reduction in disease 
pathogenesis ( Fig 2, C). Lung tissue sections show a dramatic reduction in cellular infiltration 
after TGA treatment ( Fig 2, D). Thus TGA has the ability to inhibit asthma pathogenesis, even 
after disease is established. 
 
Fig 2. Tetraglycolate dampens cellular infiltration, eosinophilia, and inflammatory cytokine levels in a 
murine model of established asthma. A, An established asthma model was used, as described in the 
Methods section. After the first set of intranasal(i.n.) OVA challenges, mice began treatment with 20 μg 
of TGA every 3 days. i.p., Intraperitoneal. B, Cells in BALF were stained with the Hema 3 stain set. 
Inflammatory cells in BALF were counted, and eosinophils are represented as a percentage of total 
inflammatory cells. C, Cytokine levels in BALF were measured with a multiplex cytokine assay. D, Lung 
tissue was sectioned and stained with hematoxylin and eosin. Arrows indicate airways. Representative 
photographs are shown (n = 6-12 mice per group). *P < .05, as determined by using the Student t test 
when variances were normal or the Mann-Whitney test in the case of unequal variances. NS, 
Nonsensitized. 
TGA inhibits BALF cytokine and serum IgE levels and increases anti-inflammatory eicosanoid 
levels 
We next assessed the ability of TGA to inhibit several mediators of asthma pathogenesis in the 
disease model described in Fig 1, B. In BALF levels of the asthma-promoting cytokines IL-4 and 
IL-5 were significantly reduced in TGA-treated mice to levels approaching those of 
nonsensitized animals ( Fig 3, A). Additionally, serum IgE levels were significantly reduced in 
TGA-treated animals ( Fig 3, B). Epoxyeicosatrienoic acids are anti-inflammatory derivatives of 
arachidonic acid. 23 We used mass spectrometry to quantify EET levels in the BALF of control 
and TGA-treated mice. Surprisingly, we found 11,12-EET levels to be significantly upregulated 
in the BALF of TGA-treated mice compared with those seen in PBS-treated control animals 
( Fig 3, C). This finding is mirrored in human lung MCs, in which we find a significant increase 
in CYP1B1 RNA, a cytochrome P450 capable of producing the hydroxyeicosatetraenoic acids 
and EETs, 18 after TGA treatment ( Fig 3, D). Further experiments with purified human lung 
MCs demonstrated that both 11,12-EET and 14,15-EET significantly stabilized MCs challenged 
through FcεRI, inhibiting both degranulation and cytokine production compared with non–EET-
treated cells ( Fig 3, E). In contrast, 8,9-EET did not demonstrate any inhibition of MC mediator 
release (not shown). Although TGA-induced increases in 11,12-EET levels paralleled inhibition 
of in vivo asthma induction and stabilized human MC mediator release alone, other arachidonic 
acid derivatives were not upregulated in vivo (see Table E1 in this article's Online Repository 
at www.jacionline.org). Lastly, when B cells were incubated with TGA before challenge with 
IgE-producing stimuli, there was a significant inhibition of IgE levels in TGA-treated cells 
compared with those seen in non–TGA-treated cells ( Fig 3, F, left) that was not due to reduced 
B-cell viability ( Fig 3, F, right). Similar inhibition of IgE production was observed with EETs 
(data not shown). Together, these data indicate that TGA suppresses asthma by directly targeting 
lung MC activation or through reduced B-cell IgE production. 
 
Fig 3. Tetraglycolate significantly reduces inflammatory cytokine, eicosanoid, and serum IgE levels. 
Asthma induction and fullerene treatment is described in Fig 1, B. A, Inflammatory cytokine levels were 
measured in BALF by using a multiplex cytokine assay. B, Serum was collected after OVA intranasal 
challenge and total IgE levels were measured by using ELISA. C, Levels of 11,12-EET were measured in 
BALF by means of mass spectrometry. These values were standardized by calculating the fold change 
relative to nonsensitized (NS) animals to account for variation between experiments (n = 6-9 mice per 
group). D, Human lung MCs were pretreated with 10 μg/mL TGA overnight and activated 16 hours later 
with anti-FcεRI antibodies (1 μg/mL). Gene microarray was performed, 14 and relative gene expression 
of CYP1B1 is shown. Each condition was performed in triplicate. *P < .05, as determined by using the 
Student t test when variances were normal or the Mann-Whitney test in the case of unequal 
variances. E, Epoxygenases reduce degranulation from human lung MCs after anti-FcεRI activation. 
Cells were cultured with fixed concentrations of the indicated EET or vehicle control (VC; ethanol, 40 
μmol/L), washed, and stimulated for 20 minutes with optimal concentrations of anti-FcεRI antibodies 
(3B4; 1 mg/mL). Cells were centrifuged, and β-hexosaminidase release and cytokine production were 
determined. The data shown are the average of 2 separate experiments performed in triplicate, with means 
± SEs. The asterisk indicates statistical significance compared with the vehicle control. F, TGA inhibits 
IgE production by cultured B cells. B cells were incubated with or without TGA before being activated 
with IL-4/anti-CD40 for 8 days. Cells were centrifuged, and IgE levels in the supernatants were measured 
by using ELISA. B-cell viability was assessed by using propidium iodide staining of dead cells. The 
percentage of propidium iodide–positive cells was assessed by using a flow cytometer for the first 5 days 
of incubation, after which viability was dramatically reduced in all groups. Experiments were performed 
at least 3 times in duplicate, and representative data are shown. There are no toxic effects on these cells 
compared with B cells that are left untreated or those treated with the nontoxic antioxidant ascorbic acid. 
To confirm that the increase in EET levels was relevant to the reduced asthmatic response that 
was seen, we examined the effect of blocking the synthesis of EETs by using the inhibitor PPOH 
and the model described in Fig 1, B. The PPOH is a potent and selective inhibitor of arachidonic 
acid epoxidation 16 and is more selective for EET inhibition compared with other terminal 
acetylenic compounds. Additionally, we used an antagonist of EET activity, 14,15-EE-5(Z)E. As 
seen in Fig 4, there was a significant increase in BALF eosinophil numbers ( Fig 4, A) and 
airway constriction ( Fig 4, B) in TGA-treated mice given the EET inhibitor PPOH over those 
given TGA alone. Similar results were obtained with the EET receptor antagonist 14,15-EE-
5(Z)-E (data not shown). Lung sections show increased cellular infiltration in PPOH-treated 
mice compared with that seen in those given TGA alone ( Fig 4, C). These data indicate that 
TGA-induced production of anti-inflammatory 11,12-EET is largely responsible for inhibition of 
the asthma phenotype seen in TGA-treated mice. 
 
Fig 4. Inhibiting the induction of 11,12-EET by TGA restores the asthma phenotype. Effects of the 
inhibitor of EET, PPOH, on airway inflammation and bronchoconstriction were assessed. A, Cells in 
BALF were stained with the Hema 3 stain set. Inflammatory cells in BALF were counted, and each cell 
type is shown as a percentage of total inflammatory cells. B, Airway resistance (RL) was measured in 
response to increasing doses of methacholine. C, Representative lung sections are stained with 
hematoxylin and eosin. Arrows indicate airways. Bar = 100 μm. N = 6 mice per group. *P < .05. 
FDs do not accumulate in major organs or alter liver or kidney function 
The toxicity of FDs is still widely debated and varies based on the specific moieties added to the 
fullerene core.24 Therefore the in vivo toxicity of TGA was assessed through several methods. 
A TGA molecule containing gadolinium within the fullerene sphere 25 was administered 
intranasally to mice every 3 days for 30 days to assess accumulation. Twenty-four hours after the 
last dosage, gadolinium levels were measured in the serum and lung, spleen, liver, kidney, and 
brain tissue. Gadolinium was detected only in the lung tissue, where less than 10% of that 
injected remained, indicating the TGA is cleared from the lung. No gadolinium was detected in 
any other tissue examined (data not shown). These enzymes are present at low levels in healthy 
subjects, and large increases would suggest liver toxicity. 26 No significant differences in serum 
levels of AST/ALT were observed between treated, untreated, and nonsensitized control animals 
(seeFig E1, A, in this article's Online Repository at www.jacionline.org). No significant 
differences in serum creatinine levels 27 were seen between treated, untreated, and nonsensitized 
animals (see Fig E1, B). These initial studies suggest that TGA does not accumulate within the 
body and is not acutely toxic to the liver or kidney. 
Discussion 
There is a strong need for novel therapeutics to treat asthma; indeed, up to 55% of patients 
receiving treatment for asthma have uncontrolled symptoms.28 In this study we have shown that 
TGA is able to suppress both disease onset and reverse established disease. The latter is 
especially important because human asthma treatment always involves established disease. MCs 
play an important role in human disease, and previous publications have shown that MC-
deficient mice sensitized with OVA lacking adjuvant and challenged with OVA alone, as 
performed in this study, have diminished airway inflammation and 
bronchoconstriction.7 and 29 Additionally, we developed a model of established asthma to further 
emulate the pathogenesis of human disease because therapeutics are administered after the 
initiation of symptoms. Although murine and human anatomy differ, these models were chosen 
to best represent human pathogenesis and thus suggest that TGA (or similar FD) could have 
therapeutic efficacy in the treatment of human disease. 
Specifically, it is demonstrated that mice treated with TGA throughout OVA challenge have 
significantly less airway inflammation and bronchoconstriction compared with that seen in 
untreated animals. In fact, total inflammation and bronchoconstriction in TGA-treated animals is 
not only significantly reduced but is similar to that seen in nonsensitized control subjects. Thus 
symptoms of disease were largely reversed in these animals. Note that these studies used a model 
previously shown to use MCs.29 In studies not shown, a different asthma model that is IgE but 
not MC dependent30 was also found to be inhibited by TGA. However, when a nonallergic 
airway inflammation model that develops in both MC- and IgE-deficient mice20 was used, TGA 
had no effect on eosinophilia or cytokine production (data not shown). In the established disease 
model, as when mice were treated throughout disease development, we found that TGA dampens 
eosinophilia and cytokine levels significantly in BALF. Lung sections show massive cellular 
infiltration in untreated animals, whereas those receiving TGA have minimal cellular infiltration 
surrounding the airways. Airway hyperresponsiveness trended toward reduction in TGA-treated 
animals, but because of high variability between mice, significant differences were not observed. 
Importantly, we have demonstrated that TGA activity has novel mechanisms of action. Although 
previously published in vitro studies suggested that MC inhibition might be the predominant 
mechanism of FD inhibition, these in vivo studies suggest multipotent effects of these unique 
compounds. TGA treatment reduced the levels of BALF TH2 proinflammatory cytokines and 
reduced lung inflammation. Although IL-4 stimulates IgE production by B cells, IL-5 both 
recruits and activates eosinophils at the site of inflammation. Tetraglycolate treatment 
significantly reduces both IL-4 and IL-5 levels in BALF. Additionally, serum IgE levels were 
significantly reduced after TGA treatment and TGA suppressed IgE production from B cells. In 
contrast, a nonallergic lung inflammation model was not influenced by TGA treatment. 
Several eicosanoids derived from the cytochrome P450 pathway are relatively stable, and thus 
we measured levels of these molecules in BALF samples by using mass spectrometry. The EETs 
are consistently associated with relaxation of the bronchi and other anti-inflammatory 
actions in vivo. 23, 31 and 32 Intriguingly, 11,12-EET was consistently upregulated in BALF from 
TGA-treated mice. Further in vivo studies demonstrated that the EETs play a major role in 
dampening the asthma phenotype. Specifically, selective inhibitors of EET production, as well as 
inhibitors of EET activity, reversed the TGA-induced modulation of the OVA-induced asthma 
model. 
The in vivo results with EETs led us to examine possible mechanisms in vitro. We show, for the 
first time, that EETs stabilize human lung MCs through the inhibition of FcεRI-induced mediator 
release. The actual concentration of 11,12-EET in the BALF of TGA-treated animals averaged 
40 ng/mL ( Fig 3, C), which was determined after diluting approximately 4 to 5 times when PBS 
was used to flush out BALF. On the basis of this calculation, the concentrations of EETs 
observed in BALF (approximately 160-200 ng/mL) is approximately the same as that observed 
for maximal MC inhibition (20 μmol/L). The 11,12-EET also showed a small but significant 
decrease in IgE production from IL-4/CD40–stimulated B cells (data not shown). These results 
suggest a possible mechanism as to how EETs could block the asthmatic response. We are 
currently examining the mechanisms of how EETs could block both MC and B-cell responses 
focusing on common signaling molecules in these 2 cell types. 
The cellular source of EETs is not certain at present. However, we found that TGA upregulates 
expression of human lung MC CYP1B1, a gene involved in the production of EETs, suggesting 
MCs could be the source of 11,12-EET. Other studies have demonstrated that EETs can be 
produced by lung epithelial and endothelial cells and can relax histamine-precontracted guinea 
pig and human bronchi. 31 Furthermore, they can inhibit the upregulation of vascular cell 
adhesion molecule 1, E-selectin, and intercellular adhesion molecule 1, thus potentially limiting 
cellular infiltration of the lung. 32 Consequently, 11,12-EET upregulation is playing a significant 
role in dampening airway inflammation and bronchoconstriction in these models. Together, these 
results suggest that TGA/EETs suppress the asthmatic response through a variety of 
mechanisms, targeting both B cells and MCs. In addition, our results implicate EETs as a 
heretofore undiscovered mechanism for controlling asthma and suggest that strategies that 
induce the production of EETs might be a viable therapeutic strategy for treating asthmatic 
patients. We are currently identifying the cell types that produce EETs in response to TGA and 
are also exploring lung BALF from asthmatic patients to compare their EET levels with those of 
nonasthmatic patients. The antagonist data indicate that EETs induced by TGA are directly 
involved in the suppression seen in the asthmatic response. However, we recognize the 
possibility that TGA could have indirect effects by shunting arachidonic acid away from 
production of proinflammatory eicosanoids, such as the cysteinyl leukotrienes. Further studies 
will be required to determine whether the TGA also alters the relative levels of proinflammatory 
eicosanoids as well. 
Levels of the liver enzymes AST and ALT, which are indicative of liver toxicity when present at 
high levels in the serum, were not different between treated and untreated animals. TGA-treated 
animals had creatinine levels similar to those seen in untreated animals, and all were within the 
normal range. Thus liver and kidney function appear to be unaffected by short-term local 
administration of TGA. In addition, a TGA-like compound containing gadolinium within the 
fullerene core was developed so that its presence in tissue could be detected by using inductively 
coupled plasma neutron bombardment. After 1 month of intranasal inhalations, followed by no 
challenge for up to a week, only lung tissue contained detectable amounts of gadolinium. Thus 
TGA does not appear to build up in the body tissues, limiting the possibility of toxicity. Further 
testing will be necessary to determine the safety of these compounds in human subjects. 
In conclusion, these studies are the first to suggest the efficacy of FDs for the treatment of 
asthma through a previously undescribed mechanism involving the upregulation of anti-
inflammatory EETs. Evidence presented here suggests that specific FD compounds have the 
potential to become novel therapeutics for the treatment of asthma and pave the way to new 
research efforts focusing on the role of EETs in asthma. 
Key messages 
•The fullerene compound TGA might represent a new therapeutic option for the treatment of 
asthma. 
•Inhibition of asthma pathogenesis through the upregulation of 11,12-EET represents a novel 
inhibitory mechanism. Thus TGA might provide therapeutic benefit to patients with refractory 
asthma, and increased EET levels might be an efficacy marker for asthma therapies. 
•EETs stabilize MCs in response to FcεRI challenge. 
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Appendix 
 
Fig E1. Mice have no evident toxicity after long-term treatment with TGA. A, Levels of the liver enzymes 
AST and ALT were measured in sera of TGA-treated animals by using ELISA. B, Creatinine levels were 
measured in sera of TGA-treated animals by using ELISA. N = 6 animals per group. NS, Not significant. 
Table E1. Effect of TGA on other eicosanoids in vivo 
Eicosanoid PBS TGA 
8-HETE 4.0 ± 2.9 6.14 ± 4.13 
12-HETE 2.58 ± 1.85 2.19 ± 1.62 
15-HETE 4.37 ± 3.15 4.76 ± 3.23 
PGE2 1.78 ± 0.99 1.55 ± 0.32 
PGF2α 1.34 ± 0.18 1.35 ± 0.22 
6-Keto-PGF1α 1.22 ± 0.23 1.43 ± 0.41 
Arachidonic acid 1.66 ± 0.66 1.77 ± 1.04 
Values are presented as the mean fold change (± SD) relative to nonsensitized animals. 
Eicosanoid levels were measured in BALF by using mass spectrometry. TGA treatment does not 
significantly alter BALF levels of the noninhibitory eicosanoids listed. Fold change relative to 
nonsensitized animals was calculated to account for variation between experiments (n = 6 mice 
per group). 
HETE, Hydroxyeicosatetraenoic acid; PG, prostaglandin. 
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